

**QUALITY CHOICE MAXIMUM STRENGTH URINARY PAIN RELIEF-**  
**phenazopyridine hydrochloride tablet**  
**Chain Drug Marketing Association**

*Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.*

-----

**DRUG FACTS**

**Active ingredient (in each tablet)**

Phenazopyridine Hydrochloride 99.5 mg .

**Purpose**

Urinary Analgesic

**Warnings**

**Do not exceed recommended dosage**

**Ask doctor before use if you have**

- kidney disease
- allergies to food, preservatives or dyes
- had a hypersensitive reaction to phenazopyridine

**When using this product**

- stomach upset may occur, taking this product with or after meals may reduce stomach upset
- your urine will become reddish-orange in color. This is not harmful, but care should be taken to avoid staining clothing or other items.

**Stop use and ask doctor if**

- your symptoms last for more than 2 days
- you suspect you are having an adverse reaction to the medication

**If pregnant or breast feeding,**

Ask a health professional before use.

**Keep out of reach of children**

In case of an overdose, get medical help or contact a Poison Control Center right away.

**Use**

Fast relief from urinary pain, burning, urgency and frequency associated with urinary tract infections.

**Inactive ingredients**

Lactose, magnesium silicate, magnesium stearate, microcrystalline cellulose, pharmaceutical glaze, and sodium starch glycolate.

**Directions**

- adults and children 12 years and over:  
take 2 tablets 3 times daily with a full glass of water, with or after meals as needed
- children under 12 years: consult a doctor
- Do not use for more than 2 days (12 tablets) without consulting a doctor



## QUALITY CHOICE MAXIMUM STRENGTH URINARY PAIN RELIEF

phenazopyridine hydrochloride tablet

### Product Information

|                         |                |                    |               |
|-------------------------|----------------|--------------------|---------------|
| Product Type            | HUMAN OTC DRUG | Item Code (Source) | NDC:83324-199 |
| Route of Administration | ORAL           |                    |               |

### Active Ingredient/Active Moiety

| Ingredient Name  | Basis of Strength                | Strength |
|--|----------------------------------|----------|
| <b>PHENAZOPYRIDINE HYDROCHLORIDE</b> (UNII: 0EWG668W17)<br>(PHENAZOPYRIDINE - UNII:K2J09EMJ52) | PHENAZOPYRIDINE<br>HYDROCHLORIDE | 99.5 mg  |

### Inactive Ingredients

| Ingredient Name                              | Strength |
|--|----------|
| <b>LACTOSE</b> (UNII: J2B2A4N98G)            |          |
| <b>MAGNESIUM SILICATE</b> (UNII: 9B9691B2N9) |          |

### Product Characteristics

|        |       |              |          |
|--------|-------|--------------|----------|
| Color  | brown | Score        | no score |
| Shape  | OVAL  | Size         | 9mm      |
| Flavor |       | Imprint Code | p99      |

**Contains****Packaging**

| # | Item Code        | Package Description                                     | Marketing Start Date | Marketing End Date |
|---|------------------|---|----------------------|--------------------|
| 1 | NDC:83324-199-12 | 1 in 1 CARTON   | 12/02/2025           |                    |
| 1 |                  | 12 in 1 BLISTER PACK; Type 0: Not a Combination Product |                      |                    |
| 2 | NDC:83324-199-24 | 1 in 1 CARTON   | 12/02/2025           |                    |
| 2 |                  | 24 in 1 BLISTER PACK; Type 0: Not a Combination Product |                      |                    |

**Marketing Information**

| Marketing Category       | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|--------------------------|--|----------------------|--------------------|
| unapproved drug<br>other |  | 12/02/2025           |                    |

**Labeler** - Chain Drug Marketing Association (011920774)**Registrant** - Reese Pharmaceutical Co (004172052)

Revised: 12/2025

Chain Drug Marketing Association